FKBPL and peptide derivatives: Novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1044-1056

  Valentine, Andrea ^a   O'Rourke, Martin ^a   Yakkundi, Anita ^a   Worthington, Jenny ^b   Hookham, Michelle ^a   Bicknell, Roy ^c   McCarthy, Helen O ^a   McClelland, Keeva ^a   McCallum, Lynn ^a   Dyer, Hayder ^a   McKeen, Hayley ^a   Waugh, David J J ^a   Roberts, Jennifer ^d   McGregor, Joanne ^d   Cotton, Graham ^d   James, Iain ^d   Harrison, Timothy ^d   Hirst, David G ^a   Robson, Tracy ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Almac Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AD 01; AL 57; BINDING PROTEIN; DOCETAXEL; ENDOSTATIN; HERMES ANTIGEN; PEPTIDE DERIVATIVE; RECOMBINANT FK 506 BINDING PROTEIN LIKE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SYNTHESIS; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICROVASCULATURE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; IMMUNOPHILINS; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; RATS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952258417     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2241     Document Type: Article

References (45)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10 (Pubitemid 37328844)
2. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
4. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8. (Pubitemid 46631341)
5. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44. (Pubitemid 44480537)
6. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85. (Pubitemid 46809172)
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
8. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
9. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-7.
10. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15;392-400.
11. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nat Rev Cancer 2008;8:942-56.
12. Thurston G, Noguera-Troise I, Yancopoulo GD. The Delta paradox: DLL4 blockade leads to more tumor vessels but less tumor growth. Nat Rev Cancer 2007;7:327-31. (Pubitemid 46652486)
13. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438;932-6. (Pubitemid 43093958)
14. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46: 165-86. (Pubitemid 36452345)
15. Cao G, Savani RC, Fehrenbach M, Lyons C, Zhang L, Coukos G, et al. Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol 2006;169:325-36.
16. Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, et al. Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radio-resistance. Int J Radiat Biol 2000;76:617-23. (Pubitemid 30345162)
17. Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, et al. A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res 1999;152:451-61. (Pubitemid 29514146)
18. Kay JE. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J 1996;2:361-85.
19. Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B, et al. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell 2005;17:237-49. (Pubitemid 40138618)
20. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, et al. A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology 2008;149:5724-5734.
21. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, et al. Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study.Repro Biol Endocrinol 2010;8:22-
22. McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, et al. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res 2010;7:1090-100.
23. Pfosser A, Thalgott M, B€uttner K, Brouet A, Feron O, Boekstegers P, et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res 2005;65:728-36. (Pubitemid 40138994)
24. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10:4813-21. (Pubitemid 38955535)
25. Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A2*J Biol Chem 1999;274:35562-70.
26. O'Rourke M, Ward C, Worthington J, McKenna J, Valentine A, Robson T, et al. Evaluation of the anti-angiogenic potential of AQ4N. Clin Cancer Res 2008;14:1502-9.
27. Tozer GM, Ameer-Beg SM, Baker J, Barber PR, Hill SA, Hodgkiss RJ, et al. Intravital imaging of tumor vascular networks using multiphoton fluorescence microscopy. Adv Drug Deliv Rev 2005;57:135-52.
28. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem BiophysRes Commun 2000; 268: 183-91. (Pubitemid 30116631)
29. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404-10.
30. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
31. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-9.
32. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595-606. (Pubitemid 44529040)
33. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, et al. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 2006;25: 6079-91. (Pubitemid 44562406)
34. Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 2000;275:1829-38. (Pubitemid 30060806)
35. Verheul HM, Pinedo HM.P ossible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7475-85.
36. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/ VEGFR pathway. Curr Clin Pharmacol 2008;3:132-43.
37. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythro-poietin synthesis. Nat Med 2006;12:793-800. (Pubitemid 44050069)
38. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2005;6: 607-614. (Pubitemid 40959689)
39. Prudovsky I, Tarantini F, Landriscina M, Neivandt D, Soldi R, Kirov A, et al. Secretion without Golgi. J Cell Biochem 2007;103:1327-43. (Pubitemid 351490704)
40. Radisky DC, Hirai Y, Bissell MJ. Delivering the message: epimorphin and mammary epithelial morphogenesis. Trends Cell Biol 2003;13: 426-34. (Pubitemid 36897647)
41. Jeffery CJ. Moonlighting proteins. Trends Biochem Sci 1999;24: 8-11. (Pubitemid 29074455)
42. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGT-Pase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008;18:251-9.
43. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
44. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001;276:36770-8.
45. Teder P, Vandivier RW, Jiang D, Resolution of lung inflammation by CD44. Science 2002;296:155-8. (Pubitemid 34280077)